person · Reporting owner

Brudnick Richard

Disclosed activity across 6 companies

Tapewire entity: 40496
SEC CIK: 0001692359

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Codiak BioSciences, Inc.CDAK · Entity 114958	See Remarks	February 16, 2022	February 18, 2022
InflaRx N.V.IFRX · Entity 5840	Director	March 18, 2026	March 18, 2026
Prime Medicine, Inc.PRME · Entity 5281	Chief Business Officer	May 20, 2025	May 22, 2025
Scholar Rock Holding CorpSRRK · Entity 3721	Director	June 04, 2026	June 08, 2026
VOLITIONRX LTDVNRX · Entity 8241	Director	January 12, 2023	January 13, 2023

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Codiak BioSciences, Inc.

Report date February 16, 2022 · Filed February 18, 2022

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.21 · Expires 2032-02-15	Direct	10,850	Reported balance After 2022-02-16 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2022-02-16 · Grant · Acquired 10,850 · Balance 10,850 F1: 25% of this option shall vest and become exercisable on February 16, 2023, with the remainder vesting in 12 equal quarterly installments thereafter.
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	16,275	Reported balance After 2022-02-16 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2022-02-16 · Grant · Acquired 16,275 · Balance 16,275 F2: Each restricted stock unit represents a contingent right to receive one share of common stock. F3: On February 16, 2022, the reporting person was granted 16,275 restricted stock units, vesting in four equal installments every six months beginning on the six month anniversary of the grant date.

Filing footnotes · ownership attribution and instrument terms

F1: 25% of this option shall vest and become exercisable on February 16, 2023, with the remainder vesting in 12 equal quarterly installments thereafter.

F2: Each restricted stock unit represents a contingent right to receive one share of common stock.

F3: On February 16, 2022, the reporting person was granted 16,275 restricted stock units, vesting in four equal installments every six months beginning on the six month anniversary of the grant date.

InflaRx N.V.

Report date March 18, 2026 · Filed March 18, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Ordinary SharesSEC Table I · non-derivative	Direct	50,000	Reported balance Holding disclosure · report date 2026-03-18 · row 1 Holding and transaction disclosures are not merged. 1 source row Row 1 · Balance 50,000
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.86 · Expires 2029-02-04	Direct	Not disclosed	Reported balance Holding disclosure · report date 2026-03-18 · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · Balance Not disclosed F1: This option was granted on February 4, 2019 and is fully vested and exercisable as of the date hereof.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.86 · Expires 2031-01-04	Direct	Not disclosed	Reported balance Holding disclosure · report date 2026-03-18 · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · Balance Not disclosed F2: This option was granted on January 4, 2021 and is fully vested and exercisable as of the date hereof.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.86 · Expires 2031-07-01	Direct	Not disclosed	Reported balance Holding disclosure · report date 2026-03-18 · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · Balance Not disclosed F3: This option was granted on July 2, 2021 and is fully vested and exercisable as of the date hereof.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.86 · Expires 2032-01-11	Direct	Not disclosed	Reported balance Holding disclosure · report date 2026-03-18 · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · Balance Not disclosed F4: This option was granted on January 12, 2022 and is fully vested and exercisable as of the date hereof.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.37 · Expires 2033-01-24	Direct	Not disclosed	Reported balance Holding disclosure · report date 2026-03-18 · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · Balance Not disclosed F5: This option was granted on January 24, 2023 and is fully vested and exercisable as of the date hereof.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.79 · Expires 2034-01-05	Direct	Not disclosed	Reported balance Holding disclosure · report date 2026-03-18 · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · Balance Not disclosed F6: This option was granted on January 5, 2024 and is fully vested and exercisable as of the date hereof.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.41 · Expires 2035-01-03	Direct	Not disclosed	Reported balance Holding disclosure · report date 2026-03-18 · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · Balance Not disclosed F7: This option was granted on January 3, 2025 and is fully vested and exercisable as of the date hereof.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.17 · Expires 2036-01-06	Direct	Not disclosed	Reported balance Holding disclosure · report date 2026-03-18 · row 9 Instrument identity requires review; Table II rows are not merged. 1 source row Row 9 · Balance Not disclosed F8: This option was granted on January 6, 2026 and will vest and become exercisable in four equal installments of 7,500 shares on each quarterly anniversary of such grant date, subject to continued service through such dates.

Filing footnotes · ownership attribution and instrument terms

F1: This option was granted on February 4, 2019 and is fully vested and exercisable as of the date hereof.

F2: This option was granted on January 4, 2021 and is fully vested and exercisable as of the date hereof.

F3: This option was granted on July 2, 2021 and is fully vested and exercisable as of the date hereof.

F4: This option was granted on January 12, 2022 and is fully vested and exercisable as of the date hereof.

F5: This option was granted on January 24, 2023 and is fully vested and exercisable as of the date hereof.

F6: This option was granted on January 5, 2024 and is fully vested and exercisable as of the date hereof.

F7: This option was granted on January 3, 2025 and is fully vested and exercisable as of the date hereof.

F8: This option was granted on January 6, 2026 and will vest and become exercisable in four equal installments of 7,500 shares on each quarterly anniversary of such grant date, subject to continued service through such dates.

Prime Medicine, Inc.

Report date May 20, 2025 · Filed May 22, 2025

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	20,000	Reported balance After 2025-05-20 transaction · row 1 1 source row Row 1 · 2025-05-20 · Purchase · Acquired 20,000 · Balance 20,000

Scholar Rock Holding Corp

Report date June 04, 2026 · Filed June 08, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	21,896	Reported balance After 2026-06-04 transaction · row 1 Account or security details depend on footnotes; rows are not merged. 1 source row Row 1 · 2026-06-04 · Grant · Acquired 6,839 · Balance 21,896 F1: Each restricted stock unit ("RSU") represents the contingent right to receive, upon vesting of the RSU, one share of the Issuer's common stock. The shares subject to this RSU vest on the earlier of June 15, 2027 or on the date of the Issuer's next Annual Meeting subject to continued service to the Issuer through such date. F2: Consists of 15,057 shares of common stock and 6,839 RSUs.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $45.33 · Expires 2036-06-04	Direct	4,310	Reported balance After 2026-06-04 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2026-06-04 · Grant · Acquired 4,310 · Balance 4,310 F3: Options to vest and become fully exercisable on the earlier of the first anniversary following the date of grant or on the date of the Issuer's next Annual Meeting, subject to continued service to the Issuer through such date.

Filing footnotes · ownership attribution and instrument terms

F1: Each restricted stock unit ("RSU") represents the contingent right to receive, upon vesting of the RSU, one share of the Issuer's common stock. The shares subject to this RSU vest on the earlier of June 15, 2027 or on the date of the Issuer's next Annual Meeting subject to continued service to the Issuer through such date.

F2: Consists of 15,057 shares of common stock and 6,839 RSUs.

F3: Options to vest and become fully exercisable on the earlier of the first anniversary following the date of grant or on the date of the Issuer's next Annual Meeting, subject to continued service to the Issuer through such date.

VOLITIONRX LTD

Report date January 12, 2023 · Filed January 13, 2023

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	27,936	Reported balance After 2023-01-12 transaction · row 1 1 source row Row 1 · 2023-01-12 · Grant · Acquired 5,625 · Balance 27,936 F1: On October 4, 2022, the reporting person was awarded 15,000 restricted stock units under the Issuer's 2015 Stock Incentive Plan, subject to vesting upon the achievement of certain corporate performance goals on or prior to December 31, 2022 and June 30, 2023 and also subject to time-based vesting. Certain of the performance goals were met, resulting in the rights with respect to 5,625 restricted stock units vesting. The restricted stock units are further subject to a 3-year time-based vesting schedule, vesting in three equal installments of 1,875 units on each of October 4, 2023, October 4, 2024 and October 4, 2025, respectively. Upon vesting and settlement, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested. As reported in October 2022, the rights with respect to 2,625 restricted stock units subject to the award previously vested and remain subject to time-based vesting.

Filing footnotes · ownership attribution and instrument terms

F1: On October 4, 2022, the reporting person was awarded 15,000 restricted stock units under the Issuer's 2015 Stock Incentive Plan, subject to vesting upon the achievement of certain corporate performance goals on or prior to December 31, 2022 and June 30, 2023 and also subject to time-based vesting. Certain of the performance goals were met, resulting in the rights with respect to 5,625 restricted stock units vesting. The restricted stock units are further subject to a 3-year time-based vesting schedule, vesting in three equal installments of 1,875 units on each of October 4, 2023, October 4, 2024 and October 4, 2025, respectively. Upon vesting and settlement, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested. As reported in October 2022, the rights with respect to 2,625 restricted stock units subject to the award previously vested and remain subject to time-based vesting.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Bioverativ Inc.

Report date March 08, 2018 · Filed March 08, 2018

Section 16 reporting ended · disclosed 2018-03-08. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2018-03-08 transaction · row 1 1 source row Row 1 · 2018-03-08 · Disposition to issuer · Disposed 22,952 · Balance 0 F1: Includes 4,911 shares subject to restricted stock units. See also note 4. F2: Pursuant to the Agreement and Plan of Merger, dated as of January 21, 2018 (the "Merger Agreement"), between the Company, Sanofi, a French soci?t? anonyme (the "Parent"), and Blink Acquisition Corp. ("Merger Sub"), on March 8, 2018, Merger Sub was merged with and into the Company, with the Company continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger"). Pursuant to the Merger Agreement, at the effective time of the Merger, each share of common stock, par value $0.001 per share, of the Company (each, a "Share") was converted into the right to receive $105.00 in cash.
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	Reported balance After 2018-03-08 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2018-03-08 · Disposition to issuer · Disposed 7,489 · Balance 0 F3: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the issuer's common stock. F4: Pursuant to the Merger Agreement, each RSU outstanding immediately prior to the consummation of the tender offer by Parent and Merger Sub to acquire all the outstanding Shares for $105.00 in cash (the "Offer") automatically and without any required action on the part of its holder became fully vested and was converted immediately prior to, and contingent upon, the consummation of the Offer into a vested right to receive a lump-sum payment in an amount equal to $105.00 for each Share underlying the RSU, less any required withholding taxes.
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	Reported balance After 2018-03-08 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2018-03-08 · Disposition to issuer · Disposed 31,818 · Balance 0 F3: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the issuer's common stock. F4: Pursuant to the Merger Agreement, each RSU outstanding immediately prior to the consummation of the tender offer by Parent and Merger Sub to acquire all the outstanding Shares for $105.00 in cash (the "Offer") automatically and without any required action on the part of its holder became fully vested and was converted immediately prior to, and contingent upon, the consummation of the Offer into a vested right to receive a lump-sum payment in an amount equal to $105.00 for each Share underlying the RSU, less any required withholding taxes.
Non-Qualified Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $44.51	Direct	Reported balance After 2018-03-08 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2018-03-08 · Disposition to issuer · Disposed 14,899 · Balance 0 F5: Pursuant to the Merger Agreement, each option outstanding immediately prior to the consummation of the Offer, whether vested or unvested, automatically became fully vested and was cancelled as of immediately prior to, and contingent upon, the consummation of the Offer in exchange for the right to receive a lump-sum cash payment in the amount of the Option Consideration, if any, less any required withholding taxes, with respect to such Option. "Option Consideration" means, with respect to any Option, an amount equal to the product of (i) the number of Shares issuable under such Option multiplied by (ii) the excess of (x) $105.00 over (y) the exercise price payable in respect of each Share issuable under such Option.
Non-Qualified Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $44.51	Direct	Reported balance After 2018-03-08 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2018-03-08 · Disposition to issuer · Disposed 29,797 · Balance 0 F5: Pursuant to the Merger Agreement, each option outstanding immediately prior to the consummation of the Offer, whether vested or unvested, automatically became fully vested and was cancelled as of immediately prior to, and contingent upon, the consummation of the Offer in exchange for the right to receive a lump-sum cash payment in the amount of the Option Consideration, if any, less any required withholding taxes, with respect to such Option. "Option Consideration" means, with respect to any Option, an amount equal to the product of (i) the number of Shares issuable under such Option multiplied by (ii) the excess of (x) $105.00 over (y) the exercise price payable in respect of each Share issuable under such Option.
Non-Qualified Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $44.51	Direct	Reported balance After 2018-03-08 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2018-03-08 · Disposition to issuer · Disposed 59,595 · Balance 0 F5: Pursuant to the Merger Agreement, each option outstanding immediately prior to the consummation of the Offer, whether vested or unvested, automatically became fully vested and was cancelled as of immediately prior to, and contingent upon, the consummation of the Offer in exchange for the right to receive a lump-sum cash payment in the amount of the Option Consideration, if any, less any required withholding taxes, with respect to such Option. "Option Consideration" means, with respect to any Option, an amount equal to the product of (i) the number of Shares issuable under such Option multiplied by (ii) the excess of (x) $105.00 over (y) the exercise price payable in respect of each Share issuable under such Option.

Filing footnotes · ownership attribution and instrument terms

F1: Includes 4,911 shares subject to restricted stock units. See also note 4.

F2: Pursuant to the Agreement and Plan of Merger, dated as of January 21, 2018 (the "Merger Agreement"), between the Company, Sanofi, a French soci?t? anonyme (the "Parent"), and Blink Acquisition Corp. ("Merger Sub"), on March 8, 2018, Merger Sub was merged with and into the Company, with the Company continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger"). Pursuant to the Merger Agreement, at the effective time of the Merger, each share of common stock, par value $0.001 per share, of the Company (each, a "Share") was converted into the right to receive $105.00 in cash.

F3: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the issuer's common stock.

F4: Pursuant to the Merger Agreement, each RSU outstanding immediately prior to the consummation of the tender offer by Parent and Merger Sub to acquire all the outstanding Shares for $105.00 in cash (the "Offer") automatically and without any required action on the part of its holder became fully vested and was converted immediately prior to, and contingent upon, the consummation of the Offer into a vested right to receive a lump-sum payment in an amount equal to $105.00 for each Share underlying the RSU, less any required withholding taxes.

F5: Pursuant to the Merger Agreement, each option outstanding immediately prior to the consummation of the Offer, whether vested or unvested, automatically became fully vested and was cancelled as of immediately prior to, and contingent upon, the consummation of the Offer in exchange for the right to receive a lump-sum cash payment in the amount of the Option Consideration, if any, less any required withholding taxes, with respect to such Option. "Option Consideration" means, with respect to any Option, an amount equal to the product of (i) the number of Shares issuable under such Option multiplied by (ii) the excess of (x) $105.00 over (y) the exercise price payable in respect of each Share issuable under such Option.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
June 04, 2026 Filed Jun 8, 2026 20:54 UTC	Scholar Rock Holding Corp SRRK · Entity 3721	GrantStock Option (Right to Buy) · Derivative	4,310	$0.00 Strike: $45.33	$0.00	Disclosure SEC source: 0001104659-26-071429 · tm2617049-5_4seq1.xml · derivative · entry 2 Brudnick Richard · CIK 0001692359 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,310 Underlying: Common Stock · 4,310 shares Expires 2036-06-04 F3 · derivative.exercise_date: Options to vest and become fully exercisable on the earlier of the first anniversary following the date of grant or on the date of the Issuer's next Annual Meeting, subject to continued service to the Issuer through such date. Read SEC document
June 04, 2026 Filed Jun 8, 2026 20:54 UTC	Scholar Rock Holding Corp SRRK · Entity 3721	GrantCommon Stock	6,839	$0.00	$0.00	Disclosure SEC source: 0001104659-26-071429 · tm2617049-5_4seq1.xml · nonDerivative · entry 1 Brudnick Richard · CIK 0001692359 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,896 F1 · shares: Each restricted stock unit ("RSU") represents the contingent right to receive, upon vesting of the RSU, one share of the Issuer's common stock. The shares subject to this RSU vest on the earlier of June 15, 2027 or on the date of the Issuer's next Annual Meeting subject to continued service to the Issuer through such date. F2 · balance_after: Consists of 15,057 shares of common stock and 6,839 RSUs. Read SEC document
May 29, 2025 Filed May 30, 2025 20:31 UTC	Scholar Rock Holding Corp SRRK · Entity 3721	SaleCommon Stock	1,400	$30.00	$42,004.34	Disclosure SEC source: 0001415889-25-015003 · form4-05302025_040508.xml · nonDerivative · entry 2 Brudnick Richard · CIK 0001692359 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 15,057 F1 · shares: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on February 27, 2025 to cover tax withholding obligations upon the vesting and settlement of RSUs. F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $29.91 to $30.10, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. F5 · balance_after: Consists of 7,425 shares of common stock and 7,632 RSUs. Read SEC document
May 29, 2025 Filed May 30, 2025 20:31 UTC	Scholar Rock Holding Corp SRRK · Entity 3721	SaleCommon Stock	4,675	$29.63	$138,526.33	Disclosure SEC source: 0001415889-25-015003 · form4-05302025_040508.xml · nonDerivative · entry 1 Brudnick Richard · CIK 0001692359 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 16,457 F1 · shares: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on February 27, 2025 to cover tax withholding obligations upon the vesting and settlement of RSUs. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $28.90 to $29.89, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. F3 · balance_after: Consists of 8,825 shares of common stock and 7,632 RSUs. Read SEC document
May 22, 2025 Filed May 23, 2025 20:47 UTC	Scholar Rock Holding Corp SRRK · Entity 3721	GrantStock Option (Right to Buy) · Derivative	9,206	$0.00 Strike: $30.46	$0.00	Disclosure SEC source: 0001104659-25-052483 · tm2516084-7_4seq1.xml · derivative · entry 2 Brudnick Richard · CIK 0001692359 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,206 Underlying: Common Stock · 9,206 shares Expires 2035-05-22 F3 · derivative.exercise_date: Options to vest and become fully exercisable on the earlier of the first anniversary following the date of grant or on the date of the Issuer's next Annual Meeting subject to continued service to the Issuer through such date. Read SEC document
May 22, 2025 Filed May 23, 2025 20:47 UTC	Scholar Rock Holding Corp SRRK · Entity 3721	GrantCommon Stock	7,632	$0.00	$0.00	Disclosure SEC source: 0001104659-25-052483 · tm2516084-7_4seq1.xml · nonDerivative · entry 1 Brudnick Richard · CIK 0001692359 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,132 F1 · shares: Each restricted stock unit ("RSU") represents the contingent right to receive, upon vesting of the RSU, one share of the Issuer's common stock. The shares subject to this RSU vest on the earlier of June 15, 2026 or on the date of the Issuer's next Annual Meeting subject to continued service to the Issuer through such date. F2 · balance_after: Consists of 13,500 shares of Common Stock and 7,632 RSUs. Read SEC document
May 20, 2025 Filed May 22, 2025 20:22 UTC	Prime Medicine, Inc. PRME · Entity 5281	PurchaseCommon Stock	20,000	$1.19	$23,790.00	Disclosure SEC source: 0001894562-25-000030 · wk-form4_1747945354.xml · nonDerivative · entry 1 Brudnick Richard · CIK 0001692359 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 Read SEC document
February 27, 2025 Filed Mar 4, 2025 01:12 UTC	Prime Medicine, Inc. PRME · Entity 5281	GrantStock Option (right to buy) · Derivative	225,000	$0.00 Strike: $2.42	$0.00	Disclosure SEC source: 0001894562-25-000004 · wk-form4_1741050750.xml · derivative · entry 1 Brudnick Richard · CIK 0001692359 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 225,000 Underlying: Common Stock · 225,000 shares Expires 2035-02-27 F1 · derivative.exercise_date: 1/48th of the shares underlying this option vest and become exercisable in substantially equal monthly installments on each monthly anniversary of February 27, 2025, subject to the Reporting Person's continued service on each such vesting date. Read SEC document
December 05, 2024 Filed Dec 9, 2024 23:22 UTC	Prime Medicine, Inc. PRME · Entity 5281	GrantStock Option (right to buy) · Derivative	19,300	$0.00 Strike: $7.96	$0.00	Disclosure SEC source: 0001894562-24-000048 · wk-form4_1733786573.xml · derivative · entry 1 Brudnick Richard · CIK 0001692359 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 57,900 Underlying: Common Stock · 19,300 shares Expires 2032-08-04 F1 · derivative.exercise_date: Represents an option initially granted to the Reporting Person on August 4, 2022, a portion of which shares underlying this option shall vest upon the achievement of certain performance milestones. On December 5, 2024, the board of directors of the Issuer determined that one of the performance milestone conditions was achieved, resulting in the vesting of 19,300 shares. Read SEC document
June 27, 2024 Filed Jul 1, 2024 21:15 UTC	Scholar Rock Holding Corp SRRK · Entity 3721	GrantStock Option (Right to Buy) · Derivative	18,000	$0.00 Strike: $8.36	$0.00	Disclosure SEC source: 0001415889-24-018631 · form4-07012024_090731.xml · derivative · entry 2 Brudnick Richard · CIK 0001692359 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,000 Underlying: Common Stock · 18,000 shares Expires 2034-06-27 F3 · derivative.exercise_date: Options to vest and become fully exercisable on the earlier of the first anniversary following the date of grant or on the date of the Issuer's next Annual Meeting subject to continued service to the Issuer through such date. Read SEC document
June 27, 2024 Filed Jul 1, 2024 21:15 UTC	Scholar Rock Holding Corp SRRK · Entity 3721	GrantCommon Stock	13,500	$0.00	$0.00	Disclosure SEC source: 0001415889-24-018631 · form4-07012024_090731.xml · nonDerivative · entry 1 Brudnick Richard · CIK 0001692359 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,500 F1 · shares: Each restricted stock unit ("RSU") represents the contingent right to receive, upon vesting of the RSU, one share of the Issuer's common stock. The shares subject to this RSU vest on the earlier of June 15, 2025 or on the date of the Issuer's next Annual Meeting subject to continued service to the Issuer through such date. F2 · balance_after: Consists of 13,500 RSUs. Read SEC document
May 17, 2024 Filed May 21, 2024 20:11 UTC	Prime Medicine, Inc. PRME · Entity 5281	GrantStock Option (right to buy) · Derivative	19,300	$0.00 Strike: $7.96	$0.00	Disclosure SEC source: 0001894562-24-000023 · wk-form4_1716322256.xml · derivative · entry 1 Brudnick Richard · CIK 0001692359 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,600 Underlying: Common Stock · 19,300 shares Expires 2032-08-04 F1 · derivative.exercise_date: Represents an option initially granted to the Reporting Person on August 4, 2022, a portion of which shares underlying this option shall vest upon the achievement of certain performance milestones. On May 17, 2024, the board of directors of the Issuer determined that one of the performance milestone conditions was achieved, resulting in the vesting of 19,300 shares. Read SEC document
February 21, 2024 Filed Feb 23, 2024 22:04 UTC	Prime Medicine, Inc. PRME · Entity 5281	GrantStock Option (right to buy) · Derivative	135,747	$0.00 Strike: $8.49	$0.00	Disclosure SEC source: 0001894562-24-000014 · wk-form4_1708725818.xml · derivative · entry 1 Brudnick Richard · CIK 0001692359 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 135,747 Underlying: Common Stock · 135,747 shares Expires 2034-02-21 F1 · derivative.exercise_date: 1/48th of the shares underlying this option vest and become exercisable in substantially equal monthly installments on each monthly anniversary of February 21, 2024, subject to the Reporting Person's continued service on each such vesting date. Read SEC document
April 06, 2023 Filed Apr 10, 2023 20:31 UTC	Scholar Rock Holding Corp SRRK · Entity 3721	GrantStock Option (Right to Buy) · Derivative	56,000	$0.00 Strike: $7.85	$0.00	Disclosure SEC source: 0001415889-23-006405 · form4-04102023_080426.xml · derivative · entry 1 Brudnick Richard · CIK 0001692359 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 56,000 Underlying: Common Stock · 56,000 shares Expires 2033-04-06 F1 · derivative.exercise_date: Such options shall vest in equal monthly installments during the three year period following the Transaction Date; so long as such individual continues to serve as a member of the Corporation's Board of Directors on such date. Read SEC document
March 31, 2023 Filed Apr 5, 2023 00:22 UTC	Prime Medicine, Inc. PRME · Entity 5281	GrantStock Option (right to buy) · Derivative	135,747	$0.00 Strike: $12.30	$0.00	Disclosure SEC source: 0001894562-23-000004 · wf-form4_168065416536123.xml · derivative · entry 1 Brudnick Richard · CIK 0001692359 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 135,747 Underlying: Common Stock · 135,747 shares Expires 2033-03-31 F1 · derivative.exercise_date: 1/48th of the shares underlying this option vest and become exercisable in substantially equal monthly installments on each monthly anniversary of March 31, 2023, subject to the Reporting Person's continued service on each such vesting date. Read SEC document
January 12, 2023 Filed Jan 13, 2023 21:03 UTC	VOLITIONRX LTD VNRX · Entity 8241	GrantCommon Stock	5,625	$0.00	$0.00	Disclosure SEC source: 0001477932-23-000275 · form4.xml · nonDerivative · entry 1 Brudnick Richard · CIK 0001692359 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,936 F1 · shares: On October 4, 2022, the reporting person was awarded 15,000 restricted stock units under the Issuer's 2015 Stock Incentive Plan, subject to vesting upon the achievement of certain corporate performance goals on or prior to December 31, 2022 and June 30, 2023 and also subject to time-based vesting. Certain of the performance goals were met, resulting in the rights with respect to 5,625 restricted stock units vesting. The restricted stock units are further subject to a 3-year time-based vesting schedule, vesting in three equal installments of 1,875 units on each of October 4, 2023, October 4, 2024 and October 4, 2025, respectively. Upon vesting and settlement, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested. As reported in October 2022, the rights with respect to 2,625 restricted stock units subject to the award previously vested and remain subject to time-based vesting. Read SEC document
October 13, 2022 Filed Oct 14, 2022 20:06 UTC	VOLITIONRX LTD VNRX · Entity 8241	GrantCommon Stock	2,625	$0.00	$0.00	Disclosure SEC source: 0001477932-22-007699 · form4.xml · nonDerivative · entry 1 Brudnick Richard · CIK 0001692359 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,311 F1 · shares: On October 4, 2022, the reporting person was awarded 15,000 restricted stock units under the Issuer's 2015 Stock Incentive Plan, subject to vesting upon the achievement of certain corporate performance goals on or prior to December 31, 2022 and June 30, 2023 and also subject to time-based vesting. Certain of the performance goals were met, resulting in the rights with respect to 2,625 restricted stock units vesting. The restricted stock units are further subject to a 3-year time-based vesting schedule, vesting in three equal installments of 875 units on each of October 4, 2023, October 4, 2024 and October 4, 2025, respectively. Upon vesting and settlement, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested. Read SEC document
June 23, 2022 Filed Jun 24, 2022 20:05 UTC	VOLITIONRX LTD VNRX · Entity 8241	GrantStock Option (Right to Buy) · Derivative	5,613	$0.00 Strike: $3.40	$0.00	Disclosure SEC source: 0001477932-22-004666 · form4.xml · derivative · entry 2 Brudnick Richard · CIK 0001692359 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,635 Underlying: Common Stock · 5,613 shares Expires 2031-08-03 F2 · derivative.exercise_date: On August 3, 2021, the reporting person was granted an option to purchase 8,635 shares of common stock, subject to vesting upon achievement of certain corporate performance goals on or prior to July 1, 2022 and also subject to time-based vesting. Certain of the performance goals were met, resulting in the rights with respect to 5,613 shares vesting. The vested shares are further subject to a 2-year time based vesting schedule, vesting in two installments of 2,807 shares and 2,806 shares on each of August 3, 2022 and August 3, 2023, respectively. As reported in April 2022, the rights with respect to the remaining 3,022 shares subject to the award previously vested and remain subject to time-based vesting. F2 · balance_after: On August 3, 2021, the reporting person was granted an option to purchase 8,635 shares of common stock, subject to vesting upon achievement of certain corporate performance goals on or prior to July 1, 2022 and also subject to time-based vesting. Certain of the performance goals were met, resulting in the rights with respect to 5,613 shares vesting. The vested shares are further subject to a 2-year time based vesting schedule, vesting in two installments of 2,807 shares and 2,806 shares on each of August 3, 2022 and August 3, 2023, respectively. As reported in April 2022, the rights with respect to the remaining 3,022 shares subject to the award previously vested and remain subject to time-based vesting. Read SEC document
June 23, 2022 Filed Jun 24, 2022 20:05 UTC	VOLITIONRX LTD VNRX · Entity 8241	GrantCommon Stock	3,046	$0.00	$0.00	Disclosure SEC source: 0001477932-22-004666 · form4.xml · nonDerivative · entry 1 Brudnick Richard · CIK 0001692359 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,686 F1 · shares: On August 3, 2021, the reporting person was awarded 4,686 restricted stock units, subject to vesting upon achievement of certain corporate performance goals on or prior to July 1, 2022 and also subject to time-based vesting. Certain of the performance goals were met, resulting in the rights with respect to 3,046 restricted stock units vesting. The restricted stock units are further subject to a 2-year time-based vesting schedule, vesting in two equal installments of 1,523 units on each of August 3, 2022 and August 3, 2023, respectively. Upon vesting and settlement, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested. As reported in April 2022, the rights with respect to the remaining 1,640 restricted stock units subject to the award previously vested and remain subject to time-based vesting. Read SEC document
April 07, 2022 Filed Apr 8, 2022 20:02 UTC	VOLITIONRX LTD VNRX · Entity 8241	GrantStock Option (Right to Buy) · Derivative	3,022	$0.00 Strike: $3.40	$0.00	Disclosure SEC source: 0001477932-22-002178 · form4.xml · derivative · entry 2 Brudnick Richard · CIK 0001692359 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,022 Underlying: Common Stock · 3,022 shares Expires 2031-08-03 F2 · derivative.exercise_date: On August 3, 2021, the reporting person was granted an option to purchase 8,635 shares of common stock, subject to vesting upon achievement of certain corporate performance goals on or prior to July 1, 2022 and also subject to time-based vesting. Certain of the performance goals were met, resulting in the rights with respect to 3,022 shares vesting. The vested shares are further subject to a 2-year time based vesting schedule, vesting in two equal installments of 1,511 shares on each of August 3, 2022 and August 3, 2023, respectively. F2 · balance_after: On August 3, 2021, the reporting person was granted an option to purchase 8,635 shares of common stock, subject to vesting upon achievement of certain corporate performance goals on or prior to July 1, 2022 and also subject to time-based vesting. Certain of the performance goals were met, resulting in the rights with respect to 3,022 shares vesting. The vested shares are further subject to a 2-year time based vesting schedule, vesting in two equal installments of 1,511 shares on each of August 3, 2022 and August 3, 2023, respectively. Read SEC document
April 07, 2022 Filed Apr 8, 2022 20:02 UTC	VOLITIONRX LTD VNRX · Entity 8241	GrantCommon Stock	1,640	$0.00	$0.00	Disclosure SEC source: 0001477932-22-002178 · form4.xml · nonDerivative · entry 1 Brudnick Richard · CIK 0001692359 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,640 F1 · shares: On August 3, 2021, the reporting person was awarded 4,686 restricted stock units, subject to vesting upon achievement of certain corporate performance goals on or prior to July 1, 2022 and also subject to time-based vesting. Certain of the performance goals were met, resulting in the rights with respect to 1,640 restricted stock units vesting. The restricted stock units are further subject to a 2-year time-based vesting schedule, vesting in two equal installments of 820 units on each of August 3, 2022 and August 3, 2023, respectively. Upon vesting and settlement, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested. Read SEC document
February 16, 2022 Filed Feb 18, 2022 21:05 UTC	Codiak BioSciences, Inc. CDAK · Entity 114958	GrantRestricted Stock Units · Derivative	16,275	$0.00	$0.00	Disclosure SEC source: 0000899243-22-007015 · doc4.xml · derivative · entry 2 Brudnick Richard · CIK 0001692359 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,275 Underlying: Common Stock · 16,275 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. F3 · derivative.exercise_date: On February 16, 2022, the reporting person was granted 16,275 restricted stock units, vesting in four equal installments every six months beginning on the six month anniversary of the grant date. F3 · derivative.expiration_date: On February 16, 2022, the reporting person was granted 16,275 restricted stock units, vesting in four equal installments every six months beginning on the six month anniversary of the grant date. Read SEC document
February 16, 2022 Filed Feb 18, 2022 21:05 UTC	Codiak BioSciences, Inc. CDAK · Entity 114958	GrantStock Option (Right to Buy) · Derivative	10,850	$0.00 Strike: $5.21	$0.00	Disclosure SEC source: 0000899243-22-007015 · doc4.xml · derivative · entry 1 Brudnick Richard · CIK 0001692359 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,850 Underlying: Common Stock · 10,850 shares Expires 2032-02-15 F1 · derivative.exercise_date: 25% of this option shall vest and become exercisable on February 16, 2023, with the remainder vesting in 12 equal quarterly installments thereafter. Read SEC document
January 19, 2022 Filed Jan 21, 2022 21:06 UTC	Codiak BioSciences, Inc. CDAK · Entity 114958	GrantRestricted Stock Units · Derivative	8,400	$0.00	$0.00	Disclosure SEC source: 0000899243-22-002870 · doc4.xml · derivative · entry 2 Brudnick Richard · CIK 0001692359 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,400 Underlying: Common Stock · 8,400 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. F3 · derivative.exercise_date: On January 19, 2022, the reporting person was granted 8,400 restricted stock units, vesting in three equal annual installments beginning on the first anniversary of the grant date. F3 · derivative.expiration_date: On January 19, 2022, the reporting person was granted 8,400 restricted stock units, vesting in three equal annual installments beginning on the first anniversary of the grant date. Read SEC document
January 19, 2022 Filed Jan 21, 2022 21:06 UTC	Codiak BioSciences, Inc. CDAK · Entity 114958	GrantStock Option (Right to Buy) · Derivative	41,000	$0.00 Strike: $7.21	$0.00	Disclosure SEC source: 0000899243-22-002870 · doc4.xml · derivative · entry 1 Brudnick Richard · CIK 0001692359 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,000 Underlying: Common Stock · 41,000 shares Expires 2032-01-18 F1 · derivative.exercise_date: 25% of this option shall vest and become exercisable on January 19, 2023, with the remainder vesting in 12 equal quarterly installments thereafter. Read SEC document
March 25, 2021 Filed Mar 29, 2021 20:39 UTC	VOLITIONRX LTD VNRX · Entity 8241	GrantCommon Stock	15,000	$0.00	$0.00	Disclosure SEC source: 0001078782-21-000282 · primary_doc.xml · nonDerivative · entry 1 Brudnick Richard · CIK 0001692359 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 F1 · shares: Mr. Brudnick received restricted stock units subject to a 2-year vesting schedule, vesting as to 7,500 units on each of 03/25/22 and 03/25/23, respectively. Upon vesting and settlement, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested. Read SEC document
January 22, 2021 Filed Jan 26, 2021 21:51 UTC	Codiak BioSciences, Inc. CDAK · Entity 114958	GrantStock Option (Right to Buy) · Derivative	31,000	$0.00 Strike: $26.60	$0.00	Disclosure SEC source: 0000899243-21-003316 · doc4.xml · derivative · entry 1 Brudnick Richard · CIK 0001692359 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,000 Underlying: Common Stock · 31,000 shares Expires 2031-01-21 F1 · derivative.exercise_date: 25% of this option shall vest and become exercisable on January 22, 2022, with the remainder vesting in 12 equal quarterly installments thereafter. Read SEC document
March 08, 2018 Filed Mar 8, 2018 16:25 UTC	Bioverativ Inc. BIVV · Entity 168487	Disposition to issuerNon-Qualified Stock Option · Derivative	59,595	Not disclosed Strike: $44.51	Not disclosed	Disclosure SEC source: 0001127602-18-010636 · form4.xml · derivative · entry 6 Brudnick Richard · CIK 0001692359 · EVP, Business Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 59,595 shares Expires not disclosed F5 · shares: Pursuant to the Merger Agreement, each option outstanding immediately prior to the consummation of the Offer, whether vested or unvested, automatically became fully vested and was cancelled as of immediately prior to, and contingent upon, the consummation of the Offer in exchange for the right to receive a lump-sum cash payment in the amount of the Option Consideration, if any, less any required withholding taxes, with respect to such Option. "Option Consideration" means, with respect to any Option, an amount equal to the product of (i) the number of Shares issuable under such Option multiplied by (ii) the excess of (x) $105.00 over (y) the exercise price payable in respect of each Share issuable under such Option. F5 · price: Pursuant to the Merger Agreement, each option outstanding immediately prior to the consummation of the Offer, whether vested or unvested, automatically became fully vested and was cancelled as of immediately prior to, and contingent upon, the consummation of the Offer in exchange for the right to receive a lump-sum cash payment in the amount of the Option Consideration, if any, less any required withholding taxes, with respect to such Option. "Option Consideration" means, with respect to any Option, an amount equal to the product of (i) the number of Shares issuable under such Option multiplied by (ii) the excess of (x) $105.00 over (y) the exercise price payable in respect of each Share issuable under such Option. F5 · derivative.exercise_date: Pursuant to the Merger Agreement, each option outstanding immediately prior to the consummation of the Offer, whether vested or unvested, automatically became fully vested and was cancelled as of immediately prior to, and contingent upon, the consummation of the Offer in exchange for the right to receive a lump-sum cash payment in the amount of the Option Consideration, if any, less any required withholding taxes, with respect to such Option. "Option Consideration" means, with respect to any Option, an amount equal to the product of (i) the number of Shares issuable under such Option multiplied by (ii) the excess of (x) $105.00 over (y) the exercise price payable in respect of each Share issuable under such Option. F5 · derivative.expiration_date: Pursuant to the Merger Agreement, each option outstanding immediately prior to the consummation of the Offer, whether vested or unvested, automatically became fully vested and was cancelled as of immediately prior to, and contingent upon, the consummation of the Offer in exchange for the right to receive a lump-sum cash payment in the amount of the Option Consideration, if any, less any required withholding taxes, with respect to such Option. "Option Consideration" means, with respect to any Option, an amount equal to the product of (i) the number of Shares issuable under such Option multiplied by (ii) the excess of (x) $105.00 over (y) the exercise price payable in respect of each Share issuable under such Option. Read SEC document
March 08, 2018 Filed Mar 8, 2018 16:25 UTC	Bioverativ Inc. BIVV · Entity 168487	Disposition to issuerNon-Qualified Stock Option · Derivative	29,797	Not disclosed Strike: $44.51	Not disclosed	Disclosure SEC source: 0001127602-18-010636 · form4.xml · derivative · entry 5 Brudnick Richard · CIK 0001692359 · EVP, Business Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 29,797 shares Expires not disclosed F5 · shares: Pursuant to the Merger Agreement, each option outstanding immediately prior to the consummation of the Offer, whether vested or unvested, automatically became fully vested and was cancelled as of immediately prior to, and contingent upon, the consummation of the Offer in exchange for the right to receive a lump-sum cash payment in the amount of the Option Consideration, if any, less any required withholding taxes, with respect to such Option. "Option Consideration" means, with respect to any Option, an amount equal to the product of (i) the number of Shares issuable under such Option multiplied by (ii) the excess of (x) $105.00 over (y) the exercise price payable in respect of each Share issuable under such Option. F5 · price: Pursuant to the Merger Agreement, each option outstanding immediately prior to the consummation of the Offer, whether vested or unvested, automatically became fully vested and was cancelled as of immediately prior to, and contingent upon, the consummation of the Offer in exchange for the right to receive a lump-sum cash payment in the amount of the Option Consideration, if any, less any required withholding taxes, with respect to such Option. "Option Consideration" means, with respect to any Option, an amount equal to the product of (i) the number of Shares issuable under such Option multiplied by (ii) the excess of (x) $105.00 over (y) the exercise price payable in respect of each Share issuable under such Option. F5 · derivative.exercise_date: Pursuant to the Merger Agreement, each option outstanding immediately prior to the consummation of the Offer, whether vested or unvested, automatically became fully vested and was cancelled as of immediately prior to, and contingent upon, the consummation of the Offer in exchange for the right to receive a lump-sum cash payment in the amount of the Option Consideration, if any, less any required withholding taxes, with respect to such Option. "Option Consideration" means, with respect to any Option, an amount equal to the product of (i) the number of Shares issuable under such Option multiplied by (ii) the excess of (x) $105.00 over (y) the exercise price payable in respect of each Share issuable under such Option. F5 · derivative.expiration_date: Pursuant to the Merger Agreement, each option outstanding immediately prior to the consummation of the Offer, whether vested or unvested, automatically became fully vested and was cancelled as of immediately prior to, and contingent upon, the consummation of the Offer in exchange for the right to receive a lump-sum cash payment in the amount of the Option Consideration, if any, less any required withholding taxes, with respect to such Option. "Option Consideration" means, with respect to any Option, an amount equal to the product of (i) the number of Shares issuable under such Option multiplied by (ii) the excess of (x) $105.00 over (y) the exercise price payable in respect of each Share issuable under such Option. Read SEC document
March 08, 2018 Filed Mar 8, 2018 16:25 UTC	Bioverativ Inc. BIVV · Entity 168487	Disposition to issuerNon-Qualified Stock Option · Derivative	14,899	Not disclosed Strike: $44.51	Not disclosed	Disclosure SEC source: 0001127602-18-010636 · form4.xml · derivative · entry 4 Brudnick Richard · CIK 0001692359 · EVP, Business Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 14,899 shares Expires not disclosed F5 · shares: Pursuant to the Merger Agreement, each option outstanding immediately prior to the consummation of the Offer, whether vested or unvested, automatically became fully vested and was cancelled as of immediately prior to, and contingent upon, the consummation of the Offer in exchange for the right to receive a lump-sum cash payment in the amount of the Option Consideration, if any, less any required withholding taxes, with respect to such Option. "Option Consideration" means, with respect to any Option, an amount equal to the product of (i) the number of Shares issuable under such Option multiplied by (ii) the excess of (x) $105.00 over (y) the exercise price payable in respect of each Share issuable under such Option. F5 · price: Pursuant to the Merger Agreement, each option outstanding immediately prior to the consummation of the Offer, whether vested or unvested, automatically became fully vested and was cancelled as of immediately prior to, and contingent upon, the consummation of the Offer in exchange for the right to receive a lump-sum cash payment in the amount of the Option Consideration, if any, less any required withholding taxes, with respect to such Option. "Option Consideration" means, with respect to any Option, an amount equal to the product of (i) the number of Shares issuable under such Option multiplied by (ii) the excess of (x) $105.00 over (y) the exercise price payable in respect of each Share issuable under such Option. F5 · derivative.exercise_date: Pursuant to the Merger Agreement, each option outstanding immediately prior to the consummation of the Offer, whether vested or unvested, automatically became fully vested and was cancelled as of immediately prior to, and contingent upon, the consummation of the Offer in exchange for the right to receive a lump-sum cash payment in the amount of the Option Consideration, if any, less any required withholding taxes, with respect to such Option. "Option Consideration" means, with respect to any Option, an amount equal to the product of (i) the number of Shares issuable under such Option multiplied by (ii) the excess of (x) $105.00 over (y) the exercise price payable in respect of each Share issuable under such Option. F5 · derivative.expiration_date: Pursuant to the Merger Agreement, each option outstanding immediately prior to the consummation of the Offer, whether vested or unvested, automatically became fully vested and was cancelled as of immediately prior to, and contingent upon, the consummation of the Offer in exchange for the right to receive a lump-sum cash payment in the amount of the Option Consideration, if any, less any required withholding taxes, with respect to such Option. "Option Consideration" means, with respect to any Option, an amount equal to the product of (i) the number of Shares issuable under such Option multiplied by (ii) the excess of (x) $105.00 over (y) the exercise price payable in respect of each Share issuable under such Option. Read SEC document
March 08, 2018 Filed Mar 8, 2018 16:25 UTC	Bioverativ Inc. BIVV · Entity 168487	Disposition to issuerRestricted Stock Units · Derivative	31,818	Not disclosed	Not disclosed	Disclosure SEC source: 0001127602-18-010636 · form4.xml · derivative · entry 3 Brudnick Richard · CIK 0001692359 · EVP, Business Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 31,818 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the issuer's common stock. F4 · shares: Pursuant to the Merger Agreement, each RSU outstanding immediately prior to the consummation of the tender offer by Parent and Merger Sub to acquire all the outstanding Shares for $105.00 in cash (the "Offer") automatically and without any required action on the part of its holder became fully vested and was converted immediately prior to, and contingent upon, the consummation of the Offer into a vested right to receive a lump-sum payment in an amount equal to $105.00 for each Share underlying the RSU, less any required withholding taxes. F4 · price: Pursuant to the Merger Agreement, each RSU outstanding immediately prior to the consummation of the tender offer by Parent and Merger Sub to acquire all the outstanding Shares for $105.00 in cash (the "Offer") automatically and without any required action on the part of its holder became fully vested and was converted immediately prior to, and contingent upon, the consummation of the Offer into a vested right to receive a lump-sum payment in an amount equal to $105.00 for each Share underlying the RSU, less any required withholding taxes. F4 · derivative.exercise_date: Pursuant to the Merger Agreement, each RSU outstanding immediately prior to the consummation of the tender offer by Parent and Merger Sub to acquire all the outstanding Shares for $105.00 in cash (the "Offer") automatically and without any required action on the part of its holder became fully vested and was converted immediately prior to, and contingent upon, the consummation of the Offer into a vested right to receive a lump-sum payment in an amount equal to $105.00 for each Share underlying the RSU, less any required withholding taxes. F4 · derivative.expiration_date: Pursuant to the Merger Agreement, each RSU outstanding immediately prior to the consummation of the tender offer by Parent and Merger Sub to acquire all the outstanding Shares for $105.00 in cash (the "Offer") automatically and without any required action on the part of its holder became fully vested and was converted immediately prior to, and contingent upon, the consummation of the Offer into a vested right to receive a lump-sum payment in an amount equal to $105.00 for each Share underlying the RSU, less any required withholding taxes. Read SEC document
March 08, 2018 Filed Mar 8, 2018 16:25 UTC	Bioverativ Inc. BIVV · Entity 168487	Disposition to issuerRestricted Stock Units · Derivative	7,489	Not disclosed	Not disclosed	Disclosure SEC source: 0001127602-18-010636 · form4.xml · derivative · entry 2 Brudnick Richard · CIK 0001692359 · EVP, Business Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,489 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the issuer's common stock. F4 · shares: Pursuant to the Merger Agreement, each RSU outstanding immediately prior to the consummation of the tender offer by Parent and Merger Sub to acquire all the outstanding Shares for $105.00 in cash (the "Offer") automatically and without any required action on the part of its holder became fully vested and was converted immediately prior to, and contingent upon, the consummation of the Offer into a vested right to receive a lump-sum payment in an amount equal to $105.00 for each Share underlying the RSU, less any required withholding taxes. F4 · price: Pursuant to the Merger Agreement, each RSU outstanding immediately prior to the consummation of the tender offer by Parent and Merger Sub to acquire all the outstanding Shares for $105.00 in cash (the "Offer") automatically and without any required action on the part of its holder became fully vested and was converted immediately prior to, and contingent upon, the consummation of the Offer into a vested right to receive a lump-sum payment in an amount equal to $105.00 for each Share underlying the RSU, less any required withholding taxes. F4 · derivative.exercise_date: Pursuant to the Merger Agreement, each RSU outstanding immediately prior to the consummation of the tender offer by Parent and Merger Sub to acquire all the outstanding Shares for $105.00 in cash (the "Offer") automatically and without any required action on the part of its holder became fully vested and was converted immediately prior to, and contingent upon, the consummation of the Offer into a vested right to receive a lump-sum payment in an amount equal to $105.00 for each Share underlying the RSU, less any required withholding taxes. F4 · derivative.expiration_date: Pursuant to the Merger Agreement, each RSU outstanding immediately prior to the consummation of the tender offer by Parent and Merger Sub to acquire all the outstanding Shares for $105.00 in cash (the "Offer") automatically and without any required action on the part of its holder became fully vested and was converted immediately prior to, and contingent upon, the consummation of the Offer into a vested right to receive a lump-sum payment in an amount equal to $105.00 for each Share underlying the RSU, less any required withholding taxes. Read SEC document
March 08, 2018 Filed Mar 8, 2018 16:25 UTC	Bioverativ Inc. BIVV · Entity 168487	Disposition to issuerCommon Stock	22,952	Not disclosed	Not disclosed	Disclosure SEC source: 0001127602-18-010636 · form4.xml · nonDerivative · entry 1 Brudnick Richard · CIK 0001692359 · EVP, Business Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · shares: Includes 4,911 shares subject to restricted stock units. See also note 4. F2 · price: Pursuant to the Agreement and Plan of Merger, dated as of January 21, 2018 (the "Merger Agreement"), between the Company, Sanofi, a French soci?t? anonyme (the "Parent"), and Blink Acquisition Corp. ("Merger Sub"), on March 8, 2018, Merger Sub was merged with and into the Company, with the Company continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger"). Pursuant to the Merger Agreement, at the effective time of the Merger, each share of common stock, par value $0.001 per share, of the Company (each, a "Share") was converted into the right to receive $105.00 in cash. Read SEC document
February 23, 2018 Filed Feb 26, 2018 22:04 UTC	Bioverativ Inc. BIVV · Entity 168487	Tax withholdingCommon Stock	924	$104.74	$96,779.76	Disclosure SEC source: 0001127602-18-008433 · form4.xml · nonDerivative · entry 2 Brudnick Richard · CIK 0001692359 · EVP, Business Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,952 F1 · shares: Represents the number of shares forfeited by the reporting person to cover the payment of taxes incurred as a result of vesting of restricted stock units. Read SEC document
February 22, 2018 Filed Feb 26, 2018 22:04 UTC	Bioverativ Inc. BIVV · Entity 168487	Tax withholdingCommon Stock	1,419	$104.30	$148,001.70	Disclosure SEC source: 0001127602-18-008433 · form4.xml · nonDerivative · entry 1 Brudnick Richard · CIK 0001692359 · EVP, Business Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,876 F1 · shares: Represents the number of shares forfeited by the reporting person to cover the payment of taxes incurred as a result of vesting of restricted stock units. Read SEC document
February 14, 2018 Filed Feb 15, 2018 22:06 UTC	Bioverativ Inc. BIVV · Entity 168487	Exercise / conversionRestricted Stock Units · Derivative	3,744	$0.00	$0.00	Disclosure SEC source: 0001127602-18-006421 · form4.xml · derivative · entry 3 Brudnick Richard · CIK 0001692359 · EVP, Business Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,489 Underlying: Common Stock · 3,744 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F3 · derivative.exercise_date: The restricted stock units vest in three equal annual installments beginning on February 14, 2018. F3 · derivative.expiration_date: The restricted stock units vest in three equal annual installments beginning on February 14, 2018. Read SEC document
February 14, 2018 Filed Feb 15, 2018 22:06 UTC	Bioverativ Inc. BIVV · Entity 168487	Tax withholdingCommon Stock	1,137	$103.52	$117,702.24	Disclosure SEC source: 0001127602-18-006421 · form4.xml · nonDerivative · entry 2 Brudnick Richard · CIK 0001692359 · EVP, Business Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,295 F1 · shares: Represents the number of shares forfeited by the reporting person to cover the payment of taxes incurred as a result of vesting of restricted stock units. Read SEC document
February 14, 2018 Filed Feb 15, 2018 22:06 UTC	Bioverativ Inc. BIVV · Entity 168487	Exercise / conversionCommon Stock	3,744	$0.00	$0.00	Disclosure SEC source: 0001127602-18-006421 · form4.xml · nonDerivative · entry 1 Brudnick Richard · CIK 0001692359 · EVP, Business Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,432 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
January 31, 2018 Filed Feb 2, 2018 22:09 UTC	Bioverativ Inc. BIVV · Entity 168487	GrantRestricted Stock Units · Derivative	31,818	$0.00	$0.00	Disclosure SEC source: 0001127602-18-003804 · form4.xml · derivative · entry 1 Brudnick Richard · CIK 0001692359 · EVP, Business Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,818 Underlying: Common Stock · 31,818 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F2 · derivative.exercise_date: The restricted stock units vest in three equal annual installments beginning on January 31, 2019. F2 · derivative.expiration_date: The restricted stock units vest in three equal annual installments beginning on January 31, 2019. Read SEC document
February 28, 2017 Filed Mar 2, 2017 21:06 UTC	Bioverativ Inc. BIVV · Entity 168487	Tax withholdingCommon Stock	1,100	$43.42	$47,762.00	Disclosure SEC source: 0001127602-17-009668 · form4.xml · nonDerivative · entry 13 Brudnick Richard · CIK 0001692359 · EVP, Business Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,688 F3 · shares: Represents the number of shares forfeited by the reporting person to cover the payment of taxes incurred as a result of vesting of restricted stock units. Read SEC document
February 28, 2017 Filed Mar 2, 2017 21:06 UTC	Bioverativ Inc. BIVV · Entity 168487	Tax withholdingCommon Stock	66	$43.42	$2,865.72	Disclosure SEC source: 0001127602-17-009668 · form4.xml · nonDerivative · entry 12 Brudnick Richard · CIK 0001692359 · EVP, Business Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,788 F3 · shares: Represents the number of shares forfeited by the reporting person to cover the payment of taxes incurred as a result of vesting of restricted stock units. Read SEC document
February 28, 2017 Filed Mar 2, 2017 21:06 UTC	Bioverativ Inc. BIVV · Entity 168487	Tax withholdingCommon Stock	681	$47.76	$32,524.56	Disclosure SEC source: 0001127602-17-009668 · form4.xml · nonDerivative · entry 11 Brudnick Richard · CIK 0001692359 · EVP, Business Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,854 F3 · shares: Represents the number of shares forfeited by the reporting person to cover the payment of taxes incurred as a result of vesting of restricted stock units. Read SEC document
February 28, 2017 Filed Mar 2, 2017 21:06 UTC	Bioverativ Inc. BIVV · Entity 168487	Tax withholdingCommon Stock	339	$49.56	$16,800.84	Disclosure SEC source: 0001127602-17-009668 · form4.xml · nonDerivative · entry 10 Brudnick Richard · CIK 0001692359 · EVP, Business Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,535 F3 · shares: Represents the number of shares forfeited by the reporting person to cover the payment of taxes incurred as a result of vesting of restricted stock units. Read SEC document
February 28, 2017 Filed Mar 2, 2017 21:06 UTC	Bioverativ Inc. BIVV · Entity 168487	Tax withholdingCommon Stock	429	$43.42	$18,627.18	Disclosure SEC source: 0001127602-17-009668 · form4.xml · nonDerivative · entry 9 Brudnick Richard · CIK 0001692359 · EVP, Business Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,874 F3 · shares: Represents the number of shares forfeited by the reporting person to cover the payment of taxes incurred as a result of vesting of restricted stock units. Read SEC document
February 28, 2017 Filed Mar 2, 2017 21:06 UTC	Bioverativ Inc. BIVV · Entity 168487	Tax withholdingCommon Stock	25	$43.42	$1,085.50	Disclosure SEC source: 0001127602-17-009668 · form4.xml · nonDerivative · entry 8 Brudnick Richard · CIK 0001692359 · EVP, Business Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,303 F3 · shares: Represents the number of shares forfeited by the reporting person to cover the payment of taxes incurred as a result of vesting of restricted stock units. Read SEC document
February 28, 2017 Filed Mar 2, 2017 21:06 UTC	Bioverativ Inc. BIVV · Entity 168487	Tax withholdingCommon Stock	837	$47.76	$39,975.12	Disclosure SEC source: 0001127602-17-009668 · form4.xml · nonDerivative · entry 7 Brudnick Richard · CIK 0001692359 · EVP, Business Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,328 F3 · shares: Represents the number of shares forfeited by the reporting person to cover the payment of taxes incurred as a result of vesting of restricted stock units. Read SEC document
February 28, 2017 Filed Mar 2, 2017 21:06 UTC	Bioverativ Inc. BIVV · Entity 168487	Tax withholdingCommon Stock	411	$49.56	$20,369.16	Disclosure SEC source: 0001127602-17-009668 · form4.xml · nonDerivative · entry 6 Brudnick Richard · CIK 0001692359 · EVP, Business Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,165 F3 · shares: Represents the number of shares forfeited by the reporting person to cover the payment of taxes incurred as a result of vesting of restricted stock units. Read SEC document
February 28, 2017 Filed Mar 2, 2017 21:06 UTC	Bioverativ Inc. BIVV · Entity 168487	Tax withholdingCommon Stock	939	$43.42	$40,771.38	Disclosure SEC source: 0001127602-17-009668 · form4.xml · nonDerivative · entry 5 Brudnick Richard · CIK 0001692359 · EVP, Business Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,576 F3 · shares: Represents the number of shares forfeited by the reporting person to cover the payment of taxes incurred as a result of vesting of restricted stock units. Read SEC document
February 28, 2017 Filed Mar 2, 2017 21:06 UTC	Bioverativ Inc. BIVV · Entity 168487	Tax withholdingCommon Stock	45	$47.76	$2,149.20	Disclosure SEC source: 0001127602-17-009668 · form4.xml · nonDerivative · entry 4 Brudnick Richard · CIK 0001692359 · EVP, Business Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,515 F3 · shares: Represents the number of shares forfeited by the reporting person to cover the payment of taxes incurred as a result of vesting of restricted stock units. Read SEC document
February 28, 2017 Filed Mar 2, 2017 21:06 UTC	Bioverativ Inc. BIVV · Entity 168487	Tax withholdingCommon Stock	22	$49.56	$1,090.32	Disclosure SEC source: 0001127602-17-009668 · form4.xml · nonDerivative · entry 3 Brudnick Richard · CIK 0001692359 · EVP, Business Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,560 F3 · shares: Represents the number of shares forfeited by the reporting person to cover the payment of taxes incurred as a result of vesting of restricted stock units. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.